-
Mashup Score: 1
Oral and Poster Abstracts 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I multiple myeloma, Diseases, Technology and Procedures, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant, genetic profiling Ehsan Malek, MD1,2, E. Ricky Chan, PhD2,3*, Daniel Qu4*, Jane Reese2,5*, Robert Fox5*, Byung-Gyu Kim, PhD, DVM2,6*, Paolo F…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Webprogram Unavailable - 1 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Impact of Chromosome 1 Abnormalities Among Pts w/ Newly Diagnosed Multiple Myeloma: A Subgroup Analysis from the Endurance (#EAonc E1A11) Trial [oral: 12/12/21] @TMSchmidtMD et al. @myelomaMD @eaonc Abstract 467 #ASH21 https://t.co/HaaZ5tEEPT #NCT01863550 #mmsm #PrecisionMedicine https://t.co/w5KRy1KUrq
-
-
Mashup Score: 0Webprogram Unavailable - 1 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
The Longitudinal Dynamics and Natural History of Clonal Hematopoiesis [Dec 14, 2021] Margarete A Fabre et al. LBA-2 #ASH21 https://t.co/UZJgM7JOVm #leusm #mdssm #camoldx
-
-
Mashup Score: 3
Abstract. Background: Multiple myeloma (MM) patients are immunocompromised due to defects in humoral/cellular immunity and immunosuppressive therapy. Reports in
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment [Nov 23, 2021] @ovanoekelen Abstract 882 #ASH21 https://t.co/2tij6MOP92 #COVID19Vaccine #COVID19nCancer #mmsm cc @COVID19nCCC
-
-
Mashup Score: 0
gov/ct2/show/NCT04434469 .
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
RO7297089: a bispecific tetravalent antibody targeting BCMA and CD16a, (expressed on innate immune cells including NK cells/macrophages) Presented 1st at #ASH21 🛑 Efficacy results discouraging 👇 PR in 7% SD 52% #mmsm https://t.co/2EAI858RSo https://t.co/SsF3pD5AFw
-
-
Mashup Score: 0Recommendation on Advanced Molecular Testing in Hematolymphoid Malignancies in the Veterans Population - 1 year(s) ago
Abstract. The Veterans Health Administration is the largest integrated provider of cancer services in the nation, with approximately 50,000 new cancer cases dia
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Recommendation on Advanced Molecular Testing in Hematolymphoid Malignancies in the Veterans Population [Nov 5, 2021] Neff, et al. #ASH21 Abstract 4983 https://t.co/GrnqmcA0gE #PrecisionMedicine https://t.co/r5lMyFjdSy
-
-
Mashup Score: 0
Abstract. Background: Multiple myeloma (MM) patients are immunocompromised due to defects in humoral/cellular immunity and immunosuppressive therapy. Reports in
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment [Nov 23, 2021] @ovanoekelen Abst 882 #ASH21 https://t.co/2tij6MOP92 #COVID19Vaccine #COVID19nCancer #mmsm cc @COVID19nCCC
-
-
Mashup Score: 0Webprogram Unavailable - 1 year(s) ago
Webprogram is no longer available Please click HERE if you are not redirected in 5 seconds.
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
High-Dose Methotrexate Is Not Associated w/ Reduction in CNS Relapse in Pts w/ Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Pts [Sat, Dec 11, 2021] @Dr_KatLewis et al Abst 181 #ASH21 https://t.co/7wdrepRdjF #lymsm #btsm HT @tobyeyre82 https://t.co/XosimOXpnw
-
-
Mashup Score: 5Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3 - 1 year(s) ago
Abstract. The treatment landscape in acute myeloid leukemia (AML) is rapidly evolving, with multiple new therapies approved in recent years. However, the progno
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Novel investigational approaches for high-risk genetic subsets of AML: #TP53, KMT2A, #FLT3 https://t.co/ZyM7IdolDm #leusm #ASH21 https://t.co/Jg0OlJh616
-
-
Mashup Score: 0The Cancer News Daily - 2 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Cancer News Daily! https://t.co/78CvT8CvB1 Thanks to @Nature @mtmdphd @MDAndersonNews #endcancer #ash21
-
Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature That Predicts Relapse Risk and Survival Probability in Multiple Myeloma [Dec 5, 2020] @EhsanMalekMD et al. #ASH21 Abstract 1355 https://t.co/lMZfsfMWCr #mmsm #cagenome